Previous Article | Next Article ![]()
Journal of Bacteriology, June 2007, p. 3977-3986, Vol. 189, No. 11
0021-9193/07/$08.00+0 doi:10.1128/JB.01691-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Division of Oral Pathopharmacology, Department of Developmental and Reconstructive Medicine,1 Division of Microbiology and Oral Infection, Department of Molecular Microbiology and Immunology,2 Division of Orthodontics and Dentofacial Orthopedics, Department of Developmental and Reconstructive Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan,3 Department of Pharmacology, Graduate School of Dental Science, Kyushu University, Fukuoka, Japan,4 Department of Oral Microbiology, School of Dentistry, Health Sciences University of Hokkaido, Sapporo, Japan5
Received 2 November 2006/ Accepted 13 March 2007
|
|
|---|
|
|
|---|
Previously, workers have attempted to identify the hemagglutinin molecule. Okuda and Takazoe first reported that bacterial surface components of a bacterium had hemagglutinating activity (37). Ogawa and Hamada reported that P. gingivalis 381 FimA fimbriae and their oligopeptide segments have activity that agglutinates erythrocytes (35), while other researchers found that purified FimA fimbriae from P. gingivalis 381 exhibited no hemagglutinating activity (61) and that removal of fimbriae from P. gingivalis W12 cells had no effect on the hemagglutinating activity (5). Hemagglutinins with apparent molecular masses of about 24,000, 37,000, and 44,000 Da were partially purified by Inoshita et al. (20) from a culture supernatant of P. gingivalis 381. Okuda et al. (38) also partially purified hemagglutinins and obtained similar results. They reported that the hemagglutinating activity is not inhibited by sugar but is inhibited by arginine and arginine-containing peptides. Other workers have also partially purified hemagglutinins (33) (17).
P. gingivalis produces an arginine-specific cysteine proteinase (Arg-gingipain, Rgp) and a lysine-specific proteinase (Lys-gingipain, Kgp) (44). Molecular genetic analyses have revealed that Rgp is encoded by two genes, rgpA and rgpB, and that Kgp is encoded by a single gene, kgp (31). The proteins encoded by rgpA and kgp have similar structures and consist of an N-terminal propeptide region, a proteolytic domain, and C-terminal adhesin domains (HGP15 [HbR], HGP17, HGP27, and HGP44). The adhesin domains are also encoded by the hemagglutinin-encoding gene hagA; these regions are quite similar to C-terminal regions (HGP44 and HbR) of the rgpA and kgp products (1, 16). Monoclonal antibodies (MAb) 61BG1.3 and Pg-vc that inhibited hemagglutination of P. gingivalis were found to recognize a peptide in an adhesin domain (HGP44 encoded by rgpA) encoded by rgpA, kgp, and hagA (4, 24, 47). We previously found that an rgpA rgpB mutant and an rgpA kgp mutant had decreased abilities to agglutinate erythrocytes (31) and that an rgpA kgp hagA triple mutant had no hemagglutinating activity (46), suggesting that all three genes are responsible for hemagglutination. It has been reported that Kgp proteinase-adhesin complexes have hemagglutinating activity (42), while a single-chain 50-kDa form of RgpA has no such activity (41), suggesting that the proteinase domain alone is not sufficient for hemagglutination. Although these findings indicate that adhesin domain proteins are the likeliest candidates for hemagglutinin, direct evidence that identifies the molecule that is actually responsible for hemagglutination and adhesion has not been obtained yet. In order to clarify this issue, we overexpressed and purified various recombinant adhesin domain proteins derived from the HGP44 region. In this study, we obtained the first evidence showing that fully processed HGP44 can agglutinate human erythrocytes without any other HGPs or gingipains, and we determined the target molecule on the membrane of human erythrocytes.
|
|
|---|
Proteins and antibodies. Neuraminidase from Clostridium perfringens type V, chymotrypsin (C3142), human glycophorin A, human asialoglycophorin A, human transferrin, human albumin, fetuin and asialofetuin from fetal calf serum, mouse anti-human glycophorin A/B (G7650) MAb, and mouse anti-human glycophorin C (G7775) MAb were purchased from Sigma. Rabbit anti-human band 3 polyclonal antibody was obtained from Santa Cruz (Santa Cruz, CA). Mouse anti-human band 3 MAb was obtained from Abcam (Cambridge, MA). Mouse anti-human CD239 (lutheran) was purchased from Serotec (Kidlington, Oxford, United Kingdom). Rabbit anti-hemoglobin binding protein (HbR) antibody was prepared as previously described (32). Peroxidase-conjugated anti-rabbit immunoglobulin G (IgG) and peroxidase-conjugated anti-mouse IgG were purchased from Dako. Blood of cows, horses, and guinea pigs was purchased from Cosmo Bio (Tokyo, Japan).
Preparation of anti-HGP44 antibody. Recombinant glutathione S-transferase (GST)-HGP44720-1138 (rGST-HGP44720-1138) fusion protein was obtained as described previously (23). rHGP44720-1138 protein was obtained by cleavage of the GST fusion protein with PreScission protease (Amersham Pharmacia Biotech, Piscataway, NJ) used according to the manufacturer's instructions. After cleavage of the GST-HGP44720-1138 fusion protein in a glutathione-Sepharose 4B column with PreScission protease, rHGP44720-1138 was eluted from the glutathione-Sepharose 4B column with elution buffer. The eluate was then applied to the glutathione-Sepharose 4B column again to remove contaminating GST and PreScission protease. The purity of rHGP44720-1138 was then determined by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE). rHGP44720-1138 was mixed with Freund's complete adjuvant, and the mixtures were injected into mice (BALB/c and ICR) and rabbits (Japan White) subcutaneously using two booster shots of a mixture of antigen and Freund's incomplete adjuvant, which resulted in anti-HGP44 antisera. Animal care and experimental procedures were conducted in accordance with the Guidelines for Animal Experimentation of Nagasaki University and with approval of the Institutional Animal Care and Use Committee. Anti-HGP44 IgG was purified from antiserum obtained from rabbits using protein A-conjugated Sepharose 4B (Amersham Pharmacia Biotech).
Purification of His-tagged rHGP44. Primers were designed on the basis of the predicted sequences of genomic DNA coding for the HGP44 domain protein in the rgpA gene of P. gingivalis ATCC 33277. Truncated mutant HGP44 proteins were generated by removing codons by PCR mutagenesis. The sequences of the primers used were 5'-CATATGAGCGGTCAGGCCGAGATTGTTC-3' (forward primer) and 5'-CTCGAGGCGCTTGCCGTTGGCCTTGATC-3' (reverse primer) for HGP44A, 5'-CCATATGAGCGGTCAGGCCGAG-3' (forward primer) and 5'-GCTCGAGTGCCGTAATCGTCTCTTC-3' (reverse primer) for HGP44B, 5'-CCATATGATTTGGATTGCCGGACAAGGA-3' (forward primer) and 5'-GCTCGAGTGCCGTAATCGTCTCTTC-3' (reverse primer) for HGP44C, 5'-CCATATGGACGGCACGAAGATC-3' (forward primer) and 5'-GCTCGAGTGCCGTAATCGTCTCTTC-3' (reverse primer) for HGP44D, 5'-CCATATGGACGTTACGGTAGAAGGATCC-3' (forward primer) and 5'-GCTCGAGTGCCGTAATCGTCTCTTC-3' (reverse primer) for HGP44E, and 5'-CCATATGACGATCGATGCAGACGGTGACGGG-3' (forward primer) and 5'-GCTCGAGTGCCGTAATCGTCTCTTC-3' (reverse primer) for HGP44F. To verify their identities, all clones were subjected to DNA sequencing using plasmid templates and a dideoxy sequencing kit (Thermal Cycler sequencing kit; Amersham Pharmacia Biotech) with a Long Reader Sequencer 4200 (Li-Cor). The resulting fragments were then inserted into the NdeI-XhoI site of plasmid pET22b (Novagen), and the recombinant expression plasmid was then transformed into Escherichia coli BL21(DE3). Positive transformants were selected on Luria-Bertani agar plates containing carbenicillin (50 µg ml1), and colonies were used for inoculation into Luria-Bertani broth for large-scale culture. Isopropyl-ß-D-thiogalactoside (IPTG) was added to the culture at a concentration of 0.1 µM, and this was followed by incubation for 2 h to overproduce the recombinant proteins. The recombinant proteins were purified by using the Ni-nitrilotriacetic acid purification system (Invitrogen, Carlsbad, CA). In this study, hexahistidine (His6)-tagged rHGP44 proteins were used unless indicated otherwise.
Hemagglutination assay. Human erythrocytes from type A, B, AB, and O blood were obtained from healthy human volunteers. The erythrocytes were sedimented by centrifugation, and the plasma and buffy coat were removed by aspiration. The cells were washed three times by centrifugation at 4°C in PBS. The hemagglutinating activity was determined in round-bottom microtiter plates. rHGP44 proteins were diluted to obtain a twofold dilution series in PBS, and then an equal volume of a 2% suspension of washed human erythrocytes was added. The mixtures were incubated at room temperature for 60 min. Human erythrocytes pretreated with neuraminidase (10 to 100 mU; Sigma) in PBS for 1 h at 37°C were also used to examine hemagglutination.
ELISA for binding of synthetic peptides to HGP44B. The interdomain regional peptide GVRSPEAIRGRIQGTWRQKT (Pep-1) corresponding to residues 1083 to 1102, peptide GVASPEAIRGAIQGTWAQKT (Pep-2) in which alanine was substituted for Arg1085, Arg1093, and Arg1099 of Pep-1, and peptide ADHFQYGQVIPSDTHTLWPN (Pep-3) corresponding to residues 745 to 764 (phenylalanine was substituted for Asp748 because of difficulty with peptide synthesis) were obtained from Sigma Genosis. The abilities of these peptides to bind to HGP44B were determined by an enzyme-linked immunosorbent assay (ELISA). An ELISA plate (SUMILON 96-well ELISA plate; Sumitomo Bakelite Co., Ltd. Tokyo, Japan) was coated for 2 h at 37°C with the peptides in carbonate buffer (pH 9.0). Nonspecific sites were blocked with 1% bovine serum albumin-PBS. After washing, the plates were incubated with rHGP44B in bovine serum albumin-PBS for 2 h at 37°C. Bound HGP44B was reacted with rabbit anti-HGP44 antibody and horseradish peroxidase (HRP)-conjugated anti-rabbit immunoglobulin and was subsequently developed with o-phenylendiamine dihydrochloride.
Binding of HGP44B to erythrocyte ghost membrane proteins. Human erythrocytes were washed three times with cold PBS, and the buffy coat was carefully removed with each wash. Hemoglobin-free erythrocyte membrane white ghosts were prepared by hypotonic lysis of the washed cells in 5 mM sodium phosphate buffer (pH 8.0), essentially using the procedure of Fairbanks et al. (11). Membrane proteins on SDS-PAGE gels were electroblotted onto a polyvinylidene difluoride (PVDF) membrane. The blots were blocked with 5% skim milk for 1 h at room temperature, probed with 5 µg/ml of HGP44B overnight at 4°C, washed, incubated with anti-HGP44 antibody for 1 h at room temperature, washed, incubated with HRP-conjugated secondary antibodies, and finally detected with ECL-plus (Amersham Pharmacia Biotech).
Protein cross-linking and immunoprecipitation. Human erythrocytes were washed with cold PBS as described above. The washed cells (500 µl) were incubated with or without rHGP44B (200 µg) for 60 min at room temperature. Cells were then treated with the amino group-reactive homobifunctional cross-linking agent BS3 (Pierce) as follows. BS3 was added to rHGP44B-pretreated erythrocytes at a concentration of 2 mM, and cross-linking was allowed to proceed for 30 min at room temperature. The reaction was terminated by addition of Tris-HCl (0.1 M, pH 7.4) to a final concentration of 20 mM. The cells were washed three times with PBS to remove the residual rHGP44B and BS3. Erythrocyte membrane white ghosts were prepared as described above. The white ghost membrane was then solubilized with a solution containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and protease inhibitor cocktail (Sigma). The membrane lysate was subjected to immunoprecipitation with rabbit anti-HGP44 antibody used according to the manufacturer's instructions. The resulting precipitate was subjected to 10% SDS-PAGE and immunoblot analysis.
SDS-PAGE and immunoblot analysis. SDS-PAGE was performed by using the method of Laemmli (25). The gels were stained with 0.1% Coomassie brilliant blue (CBB) R-250. For immunoblot analysis, proteins on SDS-PAGE gels were electroblotted onto a PVDF membrane. The blots were blocked with 5% skim milk for 1 h at room temperature, probed with an antibody against HGP44, glycophorin A/B, glycophorin C, band3, or lutheran overnight at 4°C, washed, incubated with HRP-conjugated secondary antibodies, and finally detected with ECL-plus (Amersham Pharmacia Biotech).
Purification of RgpB proteinase. Cell-free culture supernatant of KDP137 (rgpA kgp hagA) was obtained by centrifugation at 10,000 x g for 20 min at 4°C. Ammonium sulfate was added to the culture supernatant to obtain 75% saturation. The precipitated proteins were collected by centrifugation at 10,000 x g for 20 min and suspended in 10 mM sodium phosphate buffer (pH 7.0). After dialysis against 10 mM sodium phosphate buffer (pH 7.0) at 4°C overnight, the insoluble material was removed by centrifugation at 25,000 x g for 30 min. The remaining soluble fractions containing Rgp activity were applied to a DEAE-Sepharose CL6B column that had been equilibrated with the same buffer. After the column was washed with the same buffer, elution was performed with the buffer containing 50 and 100 mM NaCl sequentially. Fractions with proteolytic activity were eluted with 100 mM NaCl. The active fractions were purified further by Sephacryl S-100 gel filtration chromatography. The active fractions were pooled and concentrated. Enzymatic activity was assayed as described previously (22).
Surface plasmon resonance (BIACORE). The interaction between HGP44B and asialoglycophorin was analyzed with BIACORE X (BIACORE AB, Tokyo, Japan). Asialoglycophorin (100 µg ml1) in 10 mM sodium acetate (pH 4.0) was immobilized on a CM5 carboxymethyl-dextran sensor chip using the amine-coupling method. HGP44B (10 µg ml1 to 100 µg ml1) in 10 mM HEPES (pH 7.4) containing 150 mM NaCl was passed over the surface of the sensor chip at a flow rate of 20 µl min1. The interaction was monitored by determining changes in surface plasmon resonance response at 25°C. After 3 min of monitoring, the same buffer was introduced onto the sensor chip in place of the HGP44 solution to start the dissociation. Both the association rate constant (Ka) and the dissociation rate constant (Kd) were calculated by using the BIAevaluation software (BIACORE AB) and the program 1:1 (Langmuir) binding model. The dissociation constant (KD) was determined from Kd/Ka.
|
|
|---|
![]() View larger version (29K): [in a new window] |
FIG. 1. P. gingivalis-mediated hemagglutination is inhibited by anti-HGP44 antibody. (A) Domain structures and homologies of gingipain adhesins RgpA, RgpB, Kgp, and HagA. RgpA and Kgp consist of signal peptide, propeptide, mature proteinase, and adhesin domain regions (HGP44, HbR, HGP17, and HGP27). RgpB has signal peptide, propeptide, and RgpB proteinase domain regions. HagA has a repeated structure consisting of HGP44-like domains and HbR. R and K indicate cleavage sites for Rgp and Kgp, respectively. (B) Amino acid sequence of HGP44 region derived from DNA sequences of rgpA. (C) Inhibition of P. gingivalis-mediated hemagglutination by anti-HGP44 antibody. P. gingivalis cells were grown in enriched BHI broth, washed with PBS, and suspended in PBS at an optical density at 540 nm of 0.8. Fifty-microliter suspensions were applied to each well of a microtiter plate and mixed with human erythrocyte suspensions and various concentrations of IgG.
|
![]() View larger version (15K): [in a new window] |
FIG. 2. rHGP44B can agglutinate human erythrocytes. (A) Schematic diagram of HGP44 and truncated mutant proteins. (B) SDS-PAGE and CBB staining pattern of purified HGP44 and truncated mutant proteins expressed as His-tagged proteins. Lanes: M, molecular markers; A, HGP44A; B, HGP44B; C, HGP44C; D, HPG44D; E, HPG44E; F, HPG44F. (C) Purified rHGP44 and truncated mutant proteins were suspended with PBS at a concentration of 50 µg ml1. The suspension and a series of twofold dilutions were applied to the wells of a microtiter plate and mixed with a human erythrocyte suspension and then incubated for 1 h at room temperature. Row A, HGP44A; row B, HGP44B; row C, HGP44C; row D, HGP44D; row E, HGP44E; row F, HGP44F.
|
![]() View larger version (36K): [in a new window] |
FIG. 3. Effects of the interdomain regional peptide. (A) Amino acid sequences of the synthetic peptides Pep-1, Pep-2, and Pep-3. (B) Inhibitory effect of the interdomain regional peptide on HGP44B-mediated hemagglutination. HGP44B (10 µg) was mixed with various concentrations of the peptides and then incubated with 1% human erythrocytes for 1 h at room temperature. (C) Binding of the interdomain regional peptide to HGP44B. Microtiter plates were coated with various concentrations of the peptides for 2 h at 37°C. After blocking and washing, the plates were incubated with 0.1 µM HGP44B. Bound HGP44B was examined by an ELISA. The values are averages of three experiments. OD490, optical density at 490 nm.
|
![]() View larger version (22K): [in a new window] |
FIG. 4. Effects of neuraminidase treatment of human erythrocytes on HGP44B-mediated hemagglutination. Neuraminidase (0, 10, 50, and 100 mU) was pretreated with 10% packed erythrocyte suspensions in PBS for 1 h at 37°C with gentle shaking. Erythrocytes were then washed three times by centrifugation with PBS. Then 100-µl portions of an HGP44B suspension and twofold serial dilutions of this suspension were applied to the wells of a microtiter plate and mixed with 100 µl of a 1% neuraminidase-treated erythrocyte suspension for 1 h at room temperature.
|
![]() View larger version (24K): [in a new window] |
FIG. 5. HGP44B binds to an 89-kDa erythrocyte membrane protein. (A) SDS-PAGE patterns of human erythrocyte membrane ghosts. The gel was stained for protein with CBB. (B, left panel) Erythrocyte membrane polypeptides were transferred from polyacrylamide gradient gels to a PVDF membrane and were incubated with anti-band 3 antibody. (B, middle panel) Membrane polypeptides were transferred to a PVDF membrane and were incubated with HGP44B. Membrane proteins that interacted with HGP44 were detected with anti-HGP44 antibody. The arrow indicates the position of an 89-kDa membrane protein that interacted with HGP44. (B, right panel) Membrane polypeptides were transferred to a PVDF membrane and were incubated with anti-glycophorin A/B antibody. The glycophorin A2 homodimer (GPA2), glycophorin AB heterodimer (GPAB), and glycophorin B2 homodimer (GPB2) were detected.
|
![]() View larger version (20K): [in a new window] |
FIG. 6. Effects of treatment of erythrocytes with chymotrypsin or RgpB proteinase on HGP44B-mediated hemagglutination and profile of erythrocyte membrane proteins. (A) Hemagglutination. Human erythrocytes (50% [vol/vol] in PBS, 100 µl) were incubated with 1 mg ml1 of chymotrypsin for 1 h at 37°C with gentle shaking. After the erythrocytes were washed with PBS for three times, they were mixed with HGP44B at concentrations of 0 to 10 µg per well for 1 h at room temperature. (B) Immunoblot analysis. Human erythrocytes (50% [vol/vol] in PBS, 100 µl) were incubated with chymotrypsin (0, 0.1, and 1.0 mg ml1) for 1 h at 37°C with gentle shaking. The erythrocytes were then washed with PBS three times. Hemoglobin-free erythrocyte membrane white ghosts were then prepared from the washed erythrocytes and subjected to SDS-PAGE and immunoblot analysis with anti-band 3 antibody (left panel) and anti-glycophorin A/B antibody (right panel). GPA2, glycophorin A2 homodimer; GPAB, glycophorin AB heterodimer; GPB2, glycophorin B2 homodimer. (C) SDS-PAGE pattern of purified RgpB proteinase. The asterisk indicates the position of a protein band of RgpB. (D) Hemagglutination. Human erythrocytes (50% [vol/vol] in PBS, 100 µl) were incubated with purified RgpB (10 U) at 37°C overnight. An HGP44B suspension (10 µg per well) and twofold serial dilutions of this suspension were applied to the wells of a microtiter plate and mixed with an erythrocyte suspension for 1 h at room temperature. (E) Immunoblot analysis. White ghosts were prepared from the RgpB-treated erythrocytes and subjected to SDS-PAGE and immunoblot analysis with anti-band 3 and anti-glycophorin A/B antibodies. The left panel shows the results of an immunoblot analysis of normal membrane protein (left lane) and RgpB-treated membrane protein (right lane) with anti-band 3 antibody; the right panel shows the results of an immunoblot analysis of normal membrane protein (left lane) and RgpB-treated membrane protein (right lane) with anti-glycophorin A/B antibody. (F) PAS staining. Membrane ghosts were prepared from untreated erythrocytes (left lane) or RgpB-treated erythrocytes (right lane) and were subjected to SDS-PAGE and PAS staining.
|
![]() View larger version (37K): [in a new window] |
FIG. 7. Cross-linking of HGP44B to erythrocyte membrane proteins. Packed human erythrocytes (500 µl) were incubated with HGP44B (200 µg) for 60 min at room temperature with gentle shaking. The chemical cross-linker BS3 was added and incubated for 30 min as described in Materials and Methods. Erythrocyte membrane ghosts were lysed and immunoprecipitated with rabbit anti-HGP44 antibody (A, B, D, E, and F) or mouse anti-glycophorin A/B (C). HGP44 was immunoprecipitated from erythrocyte membrane lysate, and the presence of HGP44 (A) and the association of glycophorin A/B (B), band 3 (D), lutheran (E), and glycophorin C (F) with HGP44 were revealed by Western blot analysis with corresponding antibodies. Glycophorin A/B was immunoprecipitated from erythrocyte membrane lysates, and the association of HGP44 with glycophorin A/B was revealed by Western blot analysis with anti-HGP44 (C). IP, immunoprecipitation; WB, Western blot analysis; GPC, glycophorin C; GP A/B, glycophorin A/B.
|
![]() View larger version (20K): [in a new window] |
FIG. 8. Effects of various host proteins on HGP44B-mediated hemagglutination. HGP44B (2.5 µM) was mixed with various concentrations of glycophorin A, asialoglycophorin, fetuin, asialofetuin, transferrin, and albumin, and the mixtures were incubated with 1% human erythrocytes in PBS for 1 h at room temperature.
|
![]() View larger version (13K): [in a new window] |
FIG. 9. Binding of HGP44B to asialoglycophorin immobilized on a CM5 sensor surface. The parameters of association and dissociation for HGP44B with asialoglycophorin were determined by surface plasmon resonance analysis (BIACORE). Sensorgrams for the binding of HGP44B to asialoglycophorin immobilized on a sensor chip were overlaid at various concentrations of HGP44B. HGP44B was injected at the concentrations (µg ml1) indicated.
|
|
|
|---|
Shibata et al. (47) reported that the PVQNLT sequence in the HGP44B region is a motif for hemagglutination. O'Brien-Simpson et al. (34) have recently reported that the FEED and GTPNPNPNPNPNPNPGT sequences in the HGP44B region may have roles in binding to fibrinogen and collagen type V and in binding to hemoglobin, respectively. Both HGP44C and HGP44D have PVQNLT, FEED, and GTPNPNPNPNPNPNPGT sequences; however, they have no hemagglutinating activity. This suggests that a hemagglutinating epitope is located in the N-terminal sequence; however, we cannot rule out the possibility that there is a hemagglutinating epitope in the N-terminally truncated HGP44B derivatives, but the proteins cannot maintain functional configurations in solution because of the loss of the N-terminal sequence. Results obtained by using the cross-linker BS3 revealed that HGP44 interacted with glycophorin A/B (Fig. 7B and C) but not with band 3, lutheran, or glycophorin C (Fig. 7D, E, and F). Furthermore, exogenous glycophorin A inhibited HGP44B-mediated hemagglutination (Fig. 8). Degradation of glycophorin AB by chymotrypsin or RgpB reduced the ability of HGP44B to agglutinate erythrocytes (Fig. 6). These results suggest that glycophorin AB is a target molecule of HGP44B on the erythrocyte membrane. Hayashi et al. (17) previously reported that the band 3 protein isolated from erythrocyte membranes by the preparative PAGE method can inhibit P. gingivalis-induced hemagglutination and bind to P. gingivalis cells, indicating that band 3 is a receptor for P. gingivalis hemagglutinin. However, a dimeric form of glycophorin AB might have been present as a contaminant in their band 3 protein sample since glycophorin AB is not stained with CBB and since the molecular mass of a dimeric form of glycophorin AB (89 kDa) is very similar to that of band 3 (
90 kDa) (50).
Asialoglycophorin inhibited hemagglutination more effectively than glycophorin A inhibited hemagglutination, and asialofetuin inhibited hemagglutination more effectively than fetuin inhibited hemagglutination. These results are consistent with the results showing that neuraminidase-treated erythrocytes were easily agglutinated by HGP44B, suggesting that HGP44B tends to interact with desialylated glycoproteins. Glycophorin A contains approximately 15 O-linked sugar chains and one N-linked sugar chain (54). The structure of N-linked oligosaccharide consists of a dibranched complex-type sugar chain with N-acetylglucosamine linked at the mannosyl residue of the core portion and fucose linked at the proximal N-acetylglucosamine residue. More than 50% of sugar chains are monosialylated at one of two galactose terminal residues, and the other terminal galactose residue is not sialylated. The remaining N-linked sugar chains are disialylated (60). Therefore, HGP44 can agglutinate erythrocytes by binding to one unsialylated branch of an N-linked sugar chain in glycophorin A in the case of native erythrocytes and by binding to two desialylated branches of glycophorin A in the case of neuraminidase-treated erythrocytes. Fetuin contains six sugar chains, at least three O-linked sugar chains, and three N-linked sugar chains (7). The N-linked sugar chains are di- or tribranched complex-type oligosaccharides, and about 80% of these chains are sialylated (14). Like glycophorin A, HGP44 can bind to unsialylated sugar chains of fetuin. Transferrin contains two N-linked dibranched sugar chains that are fully sialylated (59). Albumin is not a glycoprotein. Therefore, our results suggest that HGP44 tends to bind unsialylated sugar chains.
Human erythrocytes have a definite life span of 120 days in circulation, after which they are captured and destroyed by macrophages. The sialic acids of membrane glycoconjugates play a key role in the life span of erythrocytes. Previous studies have shown that the content of surface-bound sialic acids depends on the age of erythrocytes (9, 15, 26). Young cells contain more sialic acid residues, while ageing in vivo reduces the number of these residues. Aminoff et al. (2, 18, 56) reported that glycopeptides rich in the disaccharide Gal-(ß1-3)GalNAc could be detected in old erythrocytes but not in young erythrocytes. They clearly demonstrated the role of glycophorin in ageing and sequestration of erythrocytes, as well as the sequential desialylation of glycophorins in the in vivo ageing of erythrocytes. Our results obtained using BIACORE indicated that HGP44 binds to asialoglycophorin, suggesting that HGP44 prefers to bind senescent erythrocytes.
Suzuki et al. (52) characterized the oligosaccharide cores of various erythrocytes using human anti-I serum and Ricinus communis agglutinin by fluorescence-activated cell sorting analysis. The human anti-I serum recognizes branched N-acetyllactosaminoglycans (blood group I-type antigens), and R. communis agglutinin specifically binds Gal-(ß1-4)GlcNAc- or Gal-(ß1-3)GalNAc-containing oligosaccharides (3). Fluorescence-activated cell sorting analysis of native and neuraminidase-treated erythrocytes indicated that erythrocytes of humans, cows, and guinea pigs contained sialyl-glycans with Gal-(ß1-4)GlcNAc or Gal-(ß1-3)GalNAc chains and branched N-acetyllactosaminoglycans with sialic acids but that equine erythrocytes contained no branched N-acetyllactosaminoglycans. Since native equine erythrocytes were not agglutinated by HGP44B (unpublished data), HGP44B may prefer branched N-acetyllactosaminoglycans. However, the hemagglutinating activity of HGP44B was not affected by the presence of exogenously added sugars, including D-galactose, D-glucose, N-acetyl-D-glucosamine, N-acetyl-D-lactosamine, galacto-N-biose, and lacto-N-biose, at a concentration of 100 mM (unpublished data). Filamentous hemagglutinin of Bordetella pertussis binds sulfated sugar (13). In Streptococcus gordonii, hemagglutinin binds an
-2,3-linked sialic acid-containing protein (53). In Tannerella forsythia (formerly Bacteroides forsythus), hemagglutination is completely inhibited by N-acetylneuraminidase at a concentration less than 10 mM (30). Helicobacter pylori hemagglutinin has a similar property (8). P. gingivalis HGP44 hemagglutinin described here seems to differ from the hemagglutinins of other bacterial species. Further investigations are needed to determine the structure of the binding site of erythrocytes for P. gingivalis HGP44 hemagglutinin.
In addition to the ability to agglutinate erythrocytes, HGP44B can bind to host proteins, such as fibronectin, fibrinogen, laminin, and collagen type V (unpublished data). These matrix proteins have been reported to coat epithelial, endothelial, and fibroblast cells. Binding of HGP44B to these matrix proteins may be important for invasion of host cells and tissues by P. gingivalis. We show here that the interdomain regional peptide directly binds HGP44B and inhibits its hemagglutinating activity. The peptide also suppresses the ability of HGP44B to bind host proteins mentioned above (unpublished data). These results suggest that the interdomain regional peptide prevents adherence of P. gingivalis cells to host cells and tissues, which is the initial step in P. gingivalis infection.
This work was supported by grant-in-aid 17209057 for scientific research from the Ministry of Education, Science, Sports and Culture, Japan.
Published ahead of print on 23 March 2007. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»